HomeCompareAGLE vs QSR

AGLE vs QSR: Dividend Comparison 2026

AGLE yields 16.65% · QSR yields 3.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AGLE wins by $34.7K in total portfolio value
10 years
AGLE
AGLE
● Live price
16.65%
Share price
$12.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$59.3K
Annual income
$4,631.17
Full AGLE calculator →
QSR
QSR
● Live price
3.40%
Share price
$73.90
Annual div
$2.51
5Y div CAGR
-0.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.7K
Annual income
$386.99
Full QSR calculator →

Portfolio growth — AGLE vs QSR

📍 AGLE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAGLEQSR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AGLE + QSR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AGLE pays
QSR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AGLE
Annual income on $10K today (after 15% tax)
$1,415.49/yr
After 10yr DRIP, annual income (after tax)
$3,936.49/yr
QSR
Annual income on $10K today (after 15% tax)
$288.70/yr
After 10yr DRIP, annual income (after tax)
$328.94/yr
At 15% tax rate, AGLE beats the other by $3,607.55/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AGLE + QSR for your $10,000?

AGLE: 50%QSR: 50%
100% QSR50/50100% AGLE
Portfolio after 10yr
$42.0K
Annual income
$2,509.08/yr
Blended yield
5.97%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on QSR right now

AGLE
Analyst Ratings
3
Buy
5
Hold
Consensus: Hold
Altman Z
-1.2
Piotroski
3/9
QSR
Analyst Ratings
27
Buy
15
Hold
2
Sell
Consensus: Buy
Price Target
$81.57
+10.4% upside vs current
Range: $71.00 — $90.00
Altman Z
1.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AGLE buys
0
QSR buys
0
No recent congressional trades found for AGLE or QSR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAGLEQSR
Forward yield16.65%3.40%
Annual dividend / share$2.00$2.51
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-0.8%
Portfolio after 10y$59.3K$24.7K
Annual income after 10y$4,631.17$386.99
Total dividends collected$30.5K$3.7K
Payment frequencyquarterlyquarterly
SectorStockStock
Analyst consensusHoldBuy

Year-by-year: AGLE vs QSR ($10,000, DRIP)

YearAGLE PortfolioAGLE Income/yrQSR PortfolioQSR Income/yrGap
1← crossover$12,365$1,665.28$11,037$336.93+$1.3KAGLE
2$15,155$1,924.45$12,154$344.76+$3.0KAGLE
3$18,421$2,204.37$13,357$351.99+$5.1KAGLE
4$22,214$2,504.02$14,651$358.62+$7.6KAGLE
5$26,591$2,822.14$16,041$364.68+$10.6KAGLE
6$31,610$3,157.22$17,534$370.18+$14.1KAGLE
7$37,330$3,507.56$19,136$375.14+$18.2KAGLE
8$43,814$3,871.31$20,856$379.58+$23.0KAGLE
9$51,128$4,246.52$22,699$383.52+$28.4KAGLE
10$59,338$4,631.17$24,675$386.99+$34.7KAGLE

AGLE vs QSR: Complete Analysis 2026

AGLEStock

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Full AGLE Calculator →

QSRStock

Restaurant Brands International Inc. operates as quick service restaurant company in Canada and internationally. It operates through four segments: Tim Hortons (TH), Burger King (BK), Popeyes Louisiana Kitchen (PLK), and Firehouse Subs (FHS). The company owns and franchises TH chain of donut/coffee/tea restaurants that offer blend coffee, tea, and espresso-based hot and cold specialty drinks; and fresh baked goods, including donuts, Timbits, bagels, muffins, cookies and pastries, grilled paninis, classic sandwiches, wraps, soups, and others. It is also involved in owning and franchising BK, a fast food hamburger restaurant chain, which offers flame-grilled hamburgers, chicken and other specialty sandwiches, french fries, soft drinks, and other food items; and PLK quick service restaurants that provide Louisiana style fried chicken, chicken tenders, fried shrimp and other seafood, red beans and rice, and other regional items. In addition, the company owns and franchises FHS restaurants quick service restaurants that offer subs, soft drinks, and local specialties. As of February 15, 2022, the company had approximately 29,000 restaurants in 100 countries under the Tim Hortons, Burger King, Popeyes, And Firehouse Subs brands. Restaurant Brands International Inc. was founded in 1954 and is headquartered in Toronto, Canada.

Full QSR Calculator →
📬

Get this AGLE vs QSR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AGLE vs SCHDAGLE vs JEPIAGLE vs OAGLE vs KOAGLE vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.